ArticleClinical and translational science2025

Retrospective Analysis of Master Protocols in Tumor-Agnostic Drug Development: Evaluation of Application to Single-Agent Therapies With ORR as the Endpoint for Approval of Oncology Drugs.

Keiko Yamamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.